Aurelie Najm AurelieRheumo
4 years 10 months ago
MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ several parameters
-BMI
-waist circumference
-male gender
-age
but NOT MTX cumulative dose in a cohort of 500+ patients.
#Abst0786 @RheumNow #ACR21 https://t.co/RkSpVqN4qF https://t.co/9TENaR0WZ3
Robert B Chao, MD doctorRBC
4 years 10 months ago
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
swethaann23 swethaann23
4 years 10 months ago
Detecting inflammation in SIJ for axSpA is by MRI but Artificial intelligence convolutional network aids this:
-In the Validation set: Trained CNN ▶️91.8% accuracy; Sens 88.9% Sp 93.5%
- Holdout set: 81.5% accuracy; Sens 67%; Sp 84.5%.
Abst# 0905 #ACR21 #ACRBest @RheumNow https://t.co/qmOxk9JQOC
TheDaoIndex KDAO2011
4 years 10 months ago
Dr. R Thomas: current studies on prevention of RA:
👉oral DMARDS (MTX, HCQ)
👉biologics (RTX, abatacept)
👉 studies regulating T cells to restore tolerance
👉biomarkers of tolerant state & look at people who don't develop RA
👉 imaging as window of subclin dz. #ACR21 @rheumnow https://t.co/5bsu5459az
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21 Abs#0818: Starting biologics in moderate vs severe RA activity:
▶️ Moderate disease activity: more likely to reach LDA, remission
▶️ Severe disease: greater overall improvements, but less likely to reach remission
https://t.co/9jBtN9wUGF @Rheumnow
Richard Conway RichardPAConway
4 years 10 months ago
Tocilizumab biosimilar study. Pharmacokinetic and pharmacodynamic bioequivalence. Delighted to see this, we really need a toc biosimilar after the negative impact of supply shortages of Actemra/Roactemra this year on patients. Abstr#0823 #ACR21 @RheumNow https://t.co/MMVCwaar3r
Despite the increasing scientific knowledge on axSpAs, a substantial gap still remains. Delay in diagnosis continues to pose a threat in the early identification of patients and those already on treatment may deal with additional issues such as work productivity or quality of life.
Mrinalini Dey DrMiniDey
4 years 10 months ago
How useful are validated #PROMs in remote monitoring?
Abs#0746 Remote patient-completed assessments of disease activity may be useful in #telehealth settings- a study looking at single-item and scale measures.
#ACR21 @RheumNow
https://t.co/Xr6pqJy91q https://t.co/PKAugkgNzU
Janet Pope Janetbirdope
4 years 10 months ago
#SLE pts will.... answer in abst#0858 #ACR2021 @RheumNow
David Liew drdavidliew
4 years 10 months ago
So it's day 2 at #ACR21, and you know what that means - it's ORAL Surveillance day!
This is the figure everyone will be talking about, leading up to details in the plenary.
Why are the other bars higher than the pink bars?
ABST0831
plenty of @RheumNow coverage coming on this https://t.co/B80cSmhNV7
Eric Dein ericdeinmd
4 years 10 months ago
Abst#0788 #ACR21. Forgot to measure vitamin D?
▶️ Red cell distribution width (RDW) inversely correlates w vit D 25(OH) levels prior to MTX
⭐️ RDW ⬆️ after starting MTX, no longer correlates
https://t.co/b5EPDmGE18 @Rheumnow https://t.co/cNN14ErOmF
David Liew drdavidliew
4 years 10 months ago
ORAL Surveillance
In mod-severe RA pts >50yo, with CV RF & no hx malignancy, patient-years of exposure required for one event (vs TNFi):
MACE
tofa 5mg bid: 567
tofa 10mg bid: 319
malignancy
tofa 5mg bid: 276
tofa 10mg bid: 275
#ACR21 ABST0831 @RheumNow https://t.co/9vyXPTMFzj
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21 Abst#0793. Japanese multicenter US cohort (KUDOS) study, looked at difficult to treat (D2T) RA pts
▶️ 1/5 pts are D2T (fail 2+ b/tsDMARD, mod disease or GCs)
⭐️ Contributors of good outcomes: IL-6i (OR 9.6), concomitant MTX (OR 7.1)
@Rheumnow https://t.co/9YSa4ebQlR
